### TACTI-002: pharmacodynamic effects of combining efaliggomab alpha (soluble LAG-3) and pembrolizumab

**Forster M1,1, Felip E1,2, Mejia M1,2, Dober D1,1, Clay T1,1, Carcereny E1,3, Bondarenko I4, Peguero J5, Cobo Dols M5,1, Urso G6,1, Kainika E7,1, Garcia Ledo V1,1, Vila Martínez L1,1, Krebs M.G.1,1, Iams M.1,1, Mueller C1,1, Birgnoone C1,1 and Triebel B1,1**

**Background**

Efaliggomab alpha (efa) is soluble LAG-3 protein (LAG-3-aa) domains fused to human IgG1 backbone. Activating antigen presenting cells (APCs) with efa leads to a broader immune response to fight cancer, including increases in activated T cells (CD4/CD8) (Figure 1).

**Study design**

- **TACTI-002**: multinational, open-label, trial for 1st line advanced/metastatic NSCLC patients unsellected for PD-L1 expression.
- ENH was administered as a 30 mg subcutaneous and pembrolizumab (pembro) was administered at a standard dose of 200 mg intravenous (Figure 5).

**Endpoints**
- **Primary endpoint**: ORR by RECIST.
- **Secondary endpoints**: RECIST safety, PFS, OS.
- **Exploratory endpoints**: identify and characterize relevant biomarkers.

**Assessments**

- **Biomarkers**: pharmacodynamic effects of combining ENH (IgG1/CXCL10) was assessed in a central lab.
- **Biomarkers**: plasma concentrations of ENH (IgG1/CXCL10) was assessed in a central lab.
- **Biomarkers**: biological effects in patients with samples.

**Biomarkers**

**Figures**

- **Figure 5A**: Th1 biomarker change from baseline in patients with biomarker.</p>